EricJ.LawitzMDFAASLD,AGAF,CPI

Gastroenterology • San Antonio, TX

Hepatology & Liver Transplantation

Texas Liver Institute University of Texas Health San Antonio

Join to view full profile

Dr. Lawitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Lawitz's full profile

Already have an account?

Office
607 Camden St
Ste 108
San Antonio, TX 78215
Phone+1 210-253-3426

Fax+1 210-579-1252
Is this information wrong?

Education & Training

San Antonio Uniformed Services Health Education ConsortiumFellowship, Gastroenterology, 1996 - 1999
San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 1993 - 1996
Rush Medical College of Rush University Medical CenterClass of 1993

Certifications & Licensure

TX State Medical License 2003 - 2024
WI State Medical License 1995 - 2003
American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

FAASLD Fellow of the American Association for the Study of Liver Diseases, 2016
FAPCR Fellow of the Academy of Physicians in Clinical Research, 2016
Fellow (AGAF) American Gastroenterological Association, 2012
CPI Certified Principal Investigator,Association of Clinical Research Professionals, 2004
Join now to see all

Clinical Trials

Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C Start of enrollment: 2006 May 01
Completed
Phase 1
TD-6450 MAD Study in HCV Infected Subjects Start of enrollment: 2014 May 01
Completed
Phase 1
Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study) Start of enrollment: 2014 Jul 28
Completed
Phase 2
Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4) Start of enrollment: 2014 Oct 01
Completed
Phase 1
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis Start of enrollment: 2015 Jun 01
Completed
Phase 2
Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies Start of enrollment: 2016 Apr 30
Completed
Phase 2
A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants Start of enrollment: 2017 Jan 11
Withdrawn
Phase 1
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis Start of enrollment: 2017 Dec 27
Completed
Phase 2
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis Start of enrollment: 2018 Apr 25
Completed
Phase 2
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis Start of enrollment: 2017 Aug 30
Completed
Phase 3
A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems Start of enrollment: 2019 Mar 06
Completed
Phase 1
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2019 Nov 19
Completed
Phase 2
A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects With Severe Renal Impairment and Normal Renal Function Start of enrollment: 2020 Jul 27
Recruiting
Phase 1
Roles: Principal Investigator, Contact
CM-101 in PSC Patients -The SPRING Study Start of enrollment: 2020 Oct 01
Active, not recruiting
Phase 2
Roles: Contact
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics Start of enrollment: 2022 Jan 03
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein Start of enrollment: 2023 Mar 06
Recruiting
Phase 3
Roles: Principal Investigator
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) Start of enrollment: 2024 Mar 01
Recruiting
Phase 3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

3 citations
Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions.
Loomba, R., Vlad Ratziu, Marcus Hompesch, Mathieu Petitjean, Cindy Serdjebi, Janani S Iyer, Anil V Parwani, Dean Tai, Elisabetta Bugianesi, Kenneth Cusi, Scott L Fried...> ;Journal of Hepatology. 2024 Feb 1
Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH.
Naim Alkhouri, Carl LaCerte, Jeffrey Edwards, Fred Poordad, Eric Lawitz, Lois Lee, Sharon Karan, Sangeeta Sawhney, Mary Erickson, Leigh MacConell, Luna Zaru, Jianfen C...> ;Liver International. 2024 Apr 1
2 citations
A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis.
Philip N Newsome, Arun J Sanyal, Guy Neff, Jörn M Schattenberg, Vlad Ratziu, Judith Ertle, Jasmin Link, Alison Mackie, Corinna Schoelch, Eric Lawitz> ;Nature Communications. 2023 Nov 6
Pharmacokinetics and Safety Evaluation of Single-Dose Saroglitazar Magnesium in Subjects with Hepatic Impairment.
Eric Lawitz, Deven Parmar, Taufik Momin, Farheen Shaikh, Harilal Patel, Helen Hayes, Kimberly Swint> ;Clinical Pharmacology in Drug Development. 2023 Dec 1
Safety and pharmacokinetics of BI 685509, a soluble guanylyl cyclase activator, in patients with cirrhosis: A randomized Phase Ib study.
Eric J Lawitz, Thomas Reiberger, Jörn M Schattenberg, Corinna Schoelch, Harvey O Coxson, Diane Wong, Judith Ertle> ;Hepatology Communications. 2023 Nov 1
2 citations
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis.
Steven Flamm, Eric Lawitz, Brian Borg, Michael Charlton, Charles Landis, K Rajender Reddy, Mitchell Shiffman, Angel Alsina, Charissa Chang, Natarajan Ravendhran, Candi...> ;Viruses. 2023 Sep 29
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis.
Mary E Rinella, Hsiao D Lieu, Kris V Kowdley, Zachary D Goodman, Naim Alkhouri, Eric Lawitz, Vlad Ratziu, Manal F Abdelmalek, Vincent Wai-Sun Wong, Ziad H Younes, Aasi...> ;Hepatology. 2024 Mar 1
Pharmacokinetics, safety, and tolerability of BMS-986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment.
Hisham Qosa, Claudia H M C de Oliveira, Giovanni Cizza, Eric J Lawitz, Nicholas Colletti, Jeffrey Wetherington, Edgar D Charles, Giridhar S Tirucherai> ;Clinical and Translational Science. 2023 Oct 1
7 citations
Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis.
Arun J Sanyal, Vlad Ratziu, Rohit Loomba, Quentin M Anstee, Kris V Kowdley, Mary E Rinella, Muhammad Y Sheikh, James F Trotter, Whitfield Knapple, Eric J Lawitz, Manal...> ;Journal of Hepatology. 2023 Nov 1
High sustained virologic response rates, regardless of race or socioeconomic class, in patients treated with chronic hepatitis C in community practice using a speciali...
Saatchi Kuwelker, Eugenia Tsai, Lily Kuo, Jae Kim, Timothy Van Frank, Robert Mitchell, Ruben Ramirez, Richard Guerrero, Bryan Hanysak, Carmen Landaverde, Fabian Rodas,...> ;Medicine. 2023 Jul 28
14 citations
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
Manuel Romero-Gómez, Eric Lawitz, R Ravi Shankar, Eirum Chaudhri, Jie Liu, Raymond L H Lam, Keith D Kaufman, Samuel S Engel> ;Journal of Hepatology. 2023 Oct 1
8 citations
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study.
Rohit Loomba, Arun J Sanyal, Atsushi Nakajima, Brent A Neuschwander-Tetri, Zachary D Goodman, Stephen A Harrison, Eric J Lawitz, Nadege Gunn, Kento Imajo, Natarajan Ra...> ;Clinical Gastroenterology and Hepatology. 2024 Jan 1
8 citations
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study.
Manal F Abdelmalek, Arun J Sanyal, Atsushi Nakajima, Brent A Neuschwander-Tetri, Zachary D Goodman, Eric J Lawitz, Stephen A Harrison, Ira M Jacobson, Kento Imajo, Nad...> ;Clinical Gastroenterology and Hepatology. 2024 Jan 1
5 citations
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Gideon M Hirschfield, Mitchell L Shiffman, Aliya Gulamhusein, Kris V Kowdley, John M Vierling, Cynthia Levy, Andreas E Kremer, Ehud Zigmond, Pietro Andreone, Stuart C ...> ;Hepatology. 2023 Aug 1
5 citations
A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis...
Manal F Abdelmalek, Ayako Suzuki, Willian Sanchez, Eric Lawitz, Claudia Filozof, Hyungjin Cho, Eunhye Baek, JaeDuk Choi, Seungjae Baek> ;Contemporary Clinical Trials. 2023 Jul 1
60 citations
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
Rohit Loomba, Manal F Abdelmalek, Matthew J Armstrong, Maximilian Jara, Mette Skalshøi Kjær, Niels Krarup, Eric Lawitz, Vlad Ratziu, Arun J Sanyal, Jörn M Schattenberg...> ;The Lancet. Gastroenterology & Hepatology. 2023 Jun 1
18 citations
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.
Rohit Loomba, Daniel Q Huang, Arun J Sanyal, Quentin Mark Anstee, Michael Trauner, Eric J Lawitz, Dora Ding, Lily Ma, Catherine Jia, Andrew Billin, Ryan S Huss, Chuhan...> ;Gut. 2023 Mar 1
36 citations
Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial.
Arun J Sanyal, Patricia Lopez, Eric J Lawitz, Kathryn J Lucas, Juergen Loeffler, Won Kim, George B B Goh, Jee-Fu Huang, Carla Serra, Pietro Andreone, Yi-Cheng Chen, St...> ;Nature Medicine. 2023 Feb 1
20 citations
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b...
Rohit Loomba, Eric J Lawitz, Juan Pablo Frias, Grisell Ortiz-Lasanta, Lars Johansson, Bridgette Boggess Franey, Linda Morrow, Moti Rosenstock, Cynthia L Hartsfield, Ch...> ;The Lancet. Gastroenterology & Hepatology. 2023 Feb 1
5 citations
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B.
Jordan J Feld, Eric Lawitz, Tuan Nguyen, Jacob Lalezari, Tarek Hassanein, Paul Martin, Steven-Huy Han, Douglas Dieterich, Jeanne-Marie Giard, Guy De La Rosa, Alaa Ahma...> ;Antiviral Therapy. 2022 Dec 1
19 citations
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH.
Vlad Ratziu, Stephen A Harrison, Véronique Loustaud-Ratti, Christophe Bureau, Eric Lawitz, Manal Abdelmalek, Naim Alkhouri, Sven Francque, Hugo Girma, Raphaël Darteil,...> ;Journal of Hepatology. 2023 Mar 1
5 citations
Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients.
Eric J Lawitz, Kelvin W Li, Edna Nyangau, Tyler John Field, Jen-Chieh Chuang, Andrew Billin, Lulu Wang, Ya Wang, Ryan S Huss, Chuhan Chung, G Mani Subramanian, Robert ...> ;Journal of Lipid Research. 2022 Sep 1
6 citations
Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment.
Mark Sulkowski, Laura E Telep, Massimo Colombo, Francois Durand, K Rajender Reddy, Eric Lawitz, Marc Bourlière, Nelson Cheinquer, Stacey Scherbakovsky, Liyun Ni, Linds...> ;Alimentary Pharmacology & Therapeutics. 2022 May 1
8 citations
Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials.
Vincent Wai-Sun Wong, Won Young Tak, George Boon Bee Goh, Pin-Nan Cheng, Eric J Lawitz, Zobair M Younossi, Raj Vuppalanchi, Ziad Younes, Naim Alkhouri, Lulu Wang, Jial...> ;Clinical Gastroenterology and Hepatology. 2023 Jan 1
14 citations
Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat.
Eric J Lawitz, Bal Raj Bhandari, Peter J Ruane, Anita Kohli, Eliza Harting, Dora Ding, Jen-Chieh Chuang, Ryan S Huss, Chuhan Chung, Robert P Myers, Rohit Loomba> ;Clinical Gastroenterology and Hepatology. 2023 Jan 1
Join now to see all

Journal Articles

The Lancet Child & Adolescent Health
Arun Sanyal, Stephen A Harrison, Edgar D Charles, Stephanie Noviello, Manal F Abdelmalek, Eric J Lawitz, Rohit Loomba, The Lancet

Press Mentions

HepQuant Results Presented While Attending the 72nd AASLD Annual Meeting and AHA 2021 Annual MeetingNovember 16th, 2021
Axcella Therapeutics Launches Clinical Program to Develop Treatment for Patients with Long COVIDOctober 26th, 2021
Fatty Liver Still Unseen in the Metabolic ‘Constellation of Risk’August 23rd, 2021
Join now to see all